ABUS
Price:
$4.6266
Market Cap:
$913.93M
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technolo...[Read more]
Industry
Biotechnology
IPO Date
2007-07-26
Stock Exchange
NASDAQ
Ticker
ABUS
According to Arbutus Biopharma Corp’s latest financial reports and current stock price. The company's current PE Ratio is 5.57. This represents a change of -173.68% compared to the average of -7.56 of the last 4 quarters.
The mean historical PE Ratio of Arbutus Biopharma Corp over the last ten years is -6.55. The current 5.57 PE Ratio has changed -8607.37% with respect to the historical average. Over the past ten years (40 quarters), ABUS's PE Ratio was at its highest in in the June 2018 quarter at 182.50. The PE Ratio was at its lowest in in the December 2025 quarter at -61.67.
Average
-6.55
Median
-4.60
Minimum
-28.29
Maximum
-0.34
Discovering the peaks and valleys of Arbutus Biopharma Corp PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 869.04%
Maximum Annual PE Ratio = -0.34
Minimum Annual Increase = -89.81%
Minimum Annual PE Ratio = -28.29
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | -28.29 | 228.80% |
| 2024 | -8.61 | 51.45% |
| 2023 | -5.68 | 12.17% |
| 2022 | -5.07 | -4.95% |
| 2021 | -5.33 | 29.09% |
| 2020 | -4.13 | 299.43% |
| 2019 | -1.03 | -72.21% |
| 2018 | -3.72 | 13.39% |
| 2017 | -3.28 | 869.04% |
| 2016 | -0.34 | -89.81% |
The current PE Ratio of Arbutus Biopharma Corp (ABUS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-14.19
5-year avg
-10.60
10-year avg
-6.55
Arbutus Biopharma Corp’s PE Ratio is greater than ARS Pharmaceuticals, Inc. (-2.65), greater than Nanobiotix S.A. (-66.63), greater than GH Research PLC (-31.75), greater than Tango Therapeutics, Inc. (-34.99), greater than Bicara Therapeutics Inc. Common Stock (-9.23), greater than Septerna Inc (-48.04), greater than EyePoint Pharmaceuticals, Inc. (-3.21), greater than Kura Oncology, Inc. (-2.75), greater than ProKidney Corp. (-2.98), greater than Savara Inc. (-9.78),
| Company | PE Ratio | Market cap |
|---|---|---|
| -2.65 | $528.79M | |
| -66.63 | $2.02B | |
| -31.75 | $2.00B | |
| -34.99 | $3.61B | |
| -9.23 | $1.41B | |
| -48.04 | $1.75B | |
| -3.21 | $1.01B | |
| -2.75 | $818.30M | |
| -2.98 | $551.46M | |
| -9.78 | $1.12B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Arbutus Biopharma Corp using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Arbutus Biopharma Corp or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Arbutus Biopharma Corp's PE Ratio?
How is the PE Ratio calculated for Arbutus Biopharma Corp (ABUS)?
What is the highest PE Ratio for Arbutus Biopharma Corp (ABUS)?
What is the 3-year average PE Ratio for Arbutus Biopharma Corp (ABUS)?
What is the 5-year average PE Ratio for Arbutus Biopharma Corp (ABUS)?
How does the current PE Ratio for Arbutus Biopharma Corp (ABUS) compare to its historical average?